CA2583555C - Vaccin contre la grippe - Google Patents

Vaccin contre la grippe Download PDF

Info

Publication number
CA2583555C
CA2583555C CA2583555A CA2583555A CA2583555C CA 2583555 C CA2583555 C CA 2583555C CA 2583555 A CA2583555 A CA 2583555A CA 2583555 A CA2583555 A CA 2583555A CA 2583555 C CA2583555 C CA 2583555C
Authority
CA
Canada
Prior art keywords
influenza
vaccine
pandemic
composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2583555A
Other languages
English (en)
Other versions
CA2583555A1 (fr
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0618195A external-priority patent/GB0618195D0/en
Priority claimed from GB0619090A external-priority patent/GB0619090D0/en
Priority claimed from PCT/EP2006/010439 external-priority patent/WO2008009309A1/fr
Priority claimed from GB0623218A external-priority patent/GB0623218D0/en
Priority claimed from GB0623865A external-priority patent/GB0623865D0/en
Priority claimed from GB0625453A external-priority patent/GB0625453D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA2583555A1 publication Critical patent/CA2583555A1/fr
Application granted granted Critical
Publication of CA2583555C publication Critical patent/CA2583555C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne les formulations de vaccin monovalent contre la grippe et les campagnes de vaccination pour immuniser contre lépidémie de grippe, leur utilisation en médecine, en particulier leur utilisation pour augmenter les réponses immunitaires aux divers antigènes, et les méthodes de préparation. Plus particulièrement, la présente invention concerne les formulations immunogènes monovalentes contre linfluenza comprenant un antigène de la grippe ou une préparation antigénique de celui-ci à partir dune souche du virus de la grippe associée à léclosion dune pandémie, en combinaison avec un adjuvant démulsion huile dans leau composé dune huile métabolisable, un stérol et/ou tocophérol comme lalpha tocophérol, un émulsifiant.
CA2583555A 2006-07-17 2007-03-30 Vaccin contre la grippe Active CA2583555C (fr)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US83143706P 2006-07-17 2006-07-17
US60/831,437 2006-07-17
GB0618195A GB0618195D0 (en) 2006-09-15 2006-09-15 Influenza vaccine
GB0618195.2 2006-09-15
GB0619090A GB0619090D0 (en) 2006-09-27 2006-09-27 Influenza vaccine
GB0619090.4 2006-09-27
WOEP2006/010439 2006-10-27
PCT/EP2006/010439 WO2008009309A1 (fr) 2006-07-17 2006-10-27 Vaccin anti-grippal
GB0623218A GB0623218D0 (en) 2006-11-21 2006-11-21 Influenza vaccine
GB0623218.5 2006-11-21
GB0623865.3 2006-11-29
GB0623865A GB0623865D0 (en) 2006-11-29 2006-11-29 Influenza vaccine
GB0625453A GB0625453D0 (en) 2006-12-20 2006-12-20 Influenza vaccine
GB0625453.6 2006-12-20

Publications (2)

Publication Number Publication Date
CA2583555A1 CA2583555A1 (fr) 2008-01-17
CA2583555C true CA2583555C (fr) 2020-01-07

Family

ID=99551907

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2583555A Active CA2583555C (fr) 2006-07-17 2007-03-30 Vaccin contre la grippe

Country Status (2)

Country Link
AU (1) AU2007202129B2 (fr)
CA (1) CA2583555C (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20080254065A1 (en) * 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
DK1861120T3 (en) * 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response

Also Published As

Publication number Publication date
CA2583555A1 (fr) 2008-01-17
AU2007202129A1 (en) 2008-01-31
AU2007202129B2 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
US11564984B2 (en) Influenza vaccine
US10548969B2 (en) Oil-in-water emulsion influenza vaccine
US20080014217A1 (en) Influenza vaccine
DK1861120T3 (en) Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
US20070141078A1 (en) Influenza vaccine
US20090028903A1 (en) Novel use
EP2422810B1 (fr) Vaccin anti-grippal
US20230201329A1 (en) Influenza vaccine
AU2007202129B2 (en) Influenza vaccine

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251024

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260511